Patritumab

Summary

Patritumab (CHEMBL2109406) is a phase-3 clinical-stage antibody; indicated across 8 conditions including non-small cell lung carcinoma and lung neoplasm; with CIViC clinical evidence for 1 variant-indication association (e.g. NRG1 Expression in lung non-small cell carcinoma).

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 8 conditions
• Clinical trials: 9
• Precision-oncology evidence (CIViC): 1 variant–indication association

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2109406
Name	Patritumab
Type	Antibody
Max phase	3

Also known as: AMG 888, Patritumab, PATRITUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

8 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
non-small cell lung carcinoma	3	MONDO:0005233	EFO:0003060
lung neoplasm	3	MONDO:0021117	MONDO:0008903
upper aerodigestive tract neoplasm	2	MONDO:0005398	EFO:0004284
angiosarcoma	2	MONDO:0016982	EFO:0003968
breast neoplasm	2	MONDO:0021100	EFO:0003869
neoplasm	1	MONDO:0005070	EFO:0000616
head and neck squamous cell carcinoma	1	MONDO:0010150	EFO:0000181

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
PHASE1	4
PHASE2	2
PHASE1/PHASE2	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02134015	PHASE3	TERMINATED	Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
NCT01042379	PHASE2	RECRUITING	I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
NCT01211483	PHASE1/PHASE2	COMPLETED	Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer
NCT01512199	PHASE1/PHASE2	TERMINATED	Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)
NCT02633800	PHASE2	TERMINATED	Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN )
NCT00730470	PHASE1	COMPLETED	Phase I Study of U3P1287/01, Including Patients With Advanced Solid Tumors
NCT01479023	PHASE1	TERMINATED	Evaluation of 64Cu-DOTA-U3-1287 in Subjects With Advanced Solid Tumors
NCT01957280	PHASE1	COMPLETED	Study to Assess Pharmacokinetics, Immunogenicity and Safety/Tolerability of Patritumab (U3-1287)
NCT02350712	PHASE1	COMPLETED	Patritumab With Cetuximab and a Platinum Containing Therapy for Patients With Head and Neck Cancer

Clinical evidence (CIViC)

Variant × indication × effect (1 predictive associations from 1 curated evidence items):

Variant	Indication	Effect	Therapy	Level	CIViC
NRG1 Expression	Lung Non-small Cell Carcinoma	Sensitivity/Response	Patritumab	CIViC B	EID813

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).